The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.

Trial Details

NCT ID
NCT06609850
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • TACE
  • Ablation
  • Lenvatinb
Locations (sample)
  • Beijing, None Selected, China|39.9075,116.39723

Key Eligibility Criteria

  • 18-75 years;
  • RHCC diagnosed by imaging;
  • intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
  • the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →